Every 8-K that Iridex Corp (IRIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRIX filings page.
IRIDEX Corporation (IRIX) reports that Nasdaq has notified it of non-compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, after the stock traded below that level for the last 30 consecutive business days.
Under Nasdaq Listing Rule 5810(c)(3)(A), IRIDEX has a 180-day Cure Period to February 23, 2027 to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. If it meets other Nasdaq initial listing standards (apart from bid price) and commits to cure the deficiency, including potentially via a reverse stock split, it may receive an additional 180 days. If compliance is not regained, the common stock may be delisted, subject to an appeal process. The company states that the notice has no immediate impact on trading, business operations, or SEC reporting and that it is monitoring its stock price and evaluating options.
IRIDEX CORP (IRIX) reported second quarter 2026 revenue of $12.6 million, down 7% from $13.6 million a year earlier, as weaker retina sales offset growth in glaucoma products. Retina product revenue fell to $6.5 million from $8.0 million, while Cyclo G6 product family revenue rose 19% to $3.9 million, driven by higher probe volumes.
Gross margin was stable at 34.2% versus 34.5% last year. Operating expenses declined 5% to $5.3 million on lower general and administrative costs, but net loss widened to $1.3 million (–$0.07 per share) from $1.0 million (–$0.06). Adjusted EBITDA moved to a loss of $0.4 million from a small profit. The company was operating cash-flow positive in the quarter and ended July 4, 2026 with $4.7 million in cash and cash equivalents.
IRIDEX reaffirmed full-year 2026 revenue guidance of $51–$53 million and expects fiscal 2026 adjusted operating expenses of $19.0–$19.5 million. Management highlighted ongoing cost-transformation efforts, including shifting production to lower-cost contract manufacturers and relocating headquarters, which are intended to support long-term profitability.
IRIDEX Corporation convened its 2026 annual meeting of stockholders on June 12, 2026 but immediately adjourned it without conducting any business. The meeting is scheduled to reconvene at 8:00 a.m. Pacific Time on July 10, 2026 at the company’s Mountain View, California headquarters.
The record date for voting remains April 17, 2026, and the proposals to be considered are unchanged. Proxies already submitted remain valid and will be voted at the reconvened meeting unless properly revoked, so stockholders who have already voted are not required to act again.
Iridex Corporation reported first-quarter 2026 results, with total revenue of $11.8 million, down 1% from the prior-year period. Cyclo G6 product revenue grew 14% to $3.6 million, while retina product revenue declined to $5.8 million from $6.6 million, reflecting international supply and regulatory challenges.
Gross profit was $4.7 million, a 40% margin, compared with $5.0 million and a 43% margin a year earlier, mainly due to higher manufacturing and tariff-related costs. Operating expenses fell 4% to $5.1 million, driven by lower consulting, legal, and administrative costs, leading to a reduced net loss of $0.5 million, or $0.03 per share, versus $1.7 million, or $0.10 per share, last year.
Adjusted EBITDA was $0.3 million, down from $0.4 million in the prior-year quarter. Cash and cash equivalents were $4.6 million as of April 4, 2026. Iridex reaffirmed full-year 2026 revenue guidance of $51 million to $53 million and continues to expect positive operating cash flow for the year despite regional market disruptions.
Iridex Corporation reported improving 2025 results with strong Q4 momentum and a return to positive adjusted EBITDA. Fourth quarter revenue reached $14.7 million, up 16% year over year, driven mainly by higher retina system and glaucoma probe sales, plus an extra selling week. Q4 operating expenses fell 10% to $5.5 million, and net loss narrowed to $0.2 million or $0.01 per share.
For full year 2025, revenue grew to $52.7 million from $48.7 million, while operating expenses declined 22% to $21.8 million. Net loss improved to $4.4 million from $8.9 million, and adjusted EBITDA turned positive at $1.1 million versus a $4.3 million loss in 2024. Gross margin was 37%, down from 40%, reflecting higher manufacturing costs and inventory write-downs. Cash and cash equivalents increased to $6.0 million as of January 3, 2026.
For 2026, Iridex forecasts revenue between $51 million and $53 million, which on a pro forma basis excluding Middle East revenue in 2025 represents 1% to 5% growth. The company plans adjusted operating expenses of $19 million to $19.5 million and expects to generate positive operating cash flow for the full year.
IRIDEX Corporation entered into a new triple net lease for its future corporate headquarters at 5215 Hellyer Avenue in San Jose, California. The leased office space totals approximately 30,784 square feet, with the lease term anticipated to begin on July 1, 2026 or when operations commence.
The initial lease term runs for 90 months, with an option to extend for an additional 60 months at the greater of the existing rent or then-prevailing market rent. Annual minimum rent is approximately $646,464 for the first full lease year and approximately $665,857 for the second, then increases about 3% per year.
Minimum rent is abated for six months after the commencement date, but IRIDEX will pay its share of operating expenses, taxes, and utilities under the triple net structure. The agreement includes customary covenants, indemnities, remedies, and rights related to termination, subleasing, and transfers.
IRIDEX Corporation reported that it has released preliminary, unaudited results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The company shared these operational and financial figures in a press release dated January 12, 2026, which is attached as Exhibit 99.1. The disclosure is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
IRIDEX Corporation filed a current report to highlight its participation in the Sidoti Year-End Virtual Investor Conference on December 11, 2025. A live webcast of the presentation is scheduled to begin at 10:45 a.m. Eastern Time and will be available, along with an archived version, in the investors section of the company’s website at www.IRIDEX.com.
The company is also making available a set of presentation materials as Exhibit 99.1. These materials are being furnished, not filed, under Regulation FD, meaning they are shared for information purposes and are not treated as part of the company’s formal financial reporting under Section 18 of the Exchange Act.
IRIDEX Corporation reports that it has regained compliance with Nasdaq’s continued listing standards. Based on its Form 10-Q for the quarter ended June 28, 2025, the company now meets the Nasdaq Listing Rule 5550(b)(1) minimum stockholders’ equity requirement of $2,500,000 for the Nasdaq Capital Market.
Nasdaq has informed IRIDEX that the prior non-compliance matter is closed, removing the earlier listing deficiency. The company also issued a press release on September 9, 2025 to highlight its renewed compliance with the stockholders’ equity requirement.
IRIDEX Corporation disclosed a press release reporting its financial results for the second fiscal quarter ended June 28, 2025, and furnished that release as Exhibit 99.1 to this Form 8-K. The company specifies that the press release is furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it is incorporated by reference only as expressly stated. The filing confirms the company’s common stock trades on the Nasdaq Capital Market under the symbol IRIX and is signed by Chief Executive Officer Patrick Mercer.